Initial Statement of Beneficial Ownership (3)
November 05 2021 - 04:43PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE
COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP
OF SECURITIES
|
OMB
APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response... 0.5 |
|
Filed pursuant to Section 16(a) of the
Securities Exchange Act of 1934 or Section 30(h) of the Investment
Company Act of 1940
|
|
1. Name
and Address of Reporting Person * Teehan Brendan |
2. Date of Event Requiring Statement
(MM/DD/YYYY)
11/1/2021
|
3. Issuer Name and Ticker or Trading
Symbol ACADIA PHARMACEUTICALS INC [ACAD] |
(Last)
(First)
(Middle)
C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL,
SUITE 400 |
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)_____
Director _____
10% Owner
___X___ Officer (give title
below) _____
Other (specify below)
EVP, COO, Head of Commercial / |
(Street)
SAN
DIEGO, CA 92130
(City)
(State)
(Zip)
|
5. If Amendment, Date Original
Filed(MM/DD/YYYY)
|
6. Individual or Joint/Group
Filing(Check Applicable
Line)_X_ Form filed by One Reporting
Person
___ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Beneficially
Owned
|
1.Title of Security
(Instr. 4) |
2. Amount of Securities Beneficially Owned
(Instr. 4) |
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) |
4. Nature of Indirect Beneficial Ownership
(Instr. 5) |
Common Stock |
807 |
D |
|
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible
securities)
|
1. Title of Derivate Security
(Instr. 4) |
2. Date Exercisable and Expiration Date
(MM/DD/YYYY) |
3. Title and Amount of Securities Underlying
Derivative Security
(Instr. 4) |
4. Conversion or Exercise Price of Derivative
Security |
5. Ownership Form of Derivative Security: Direct (D)
or Indirect (I)
(Instr. 5) |
6. Nature of Indirect Beneficial Ownership
(Instr. 5) |
Date Exercisable |
Expiration Date |
Title |
Amount or Number of Shares |
Employee Stock Option (Right to Buy) |
(1) |
7/15/2028 |
Common Stock |
52500 |
$16.87 |
D |
|
Employee Stock Option (Right to Buy) |
(2) |
4/28/2029 |
Common Stock |
10993 |
$25.12 |
D |
|
Employee Stock Option (Right to Buy) |
(3) |
1/5/2030 |
Common Stock |
9336 |
$42.81 |
D |
|
Employee Stock Option (Right to Buy) |
(4) |
2/22/2031 |
Common Stock |
8152 |
$49.74 |
D |
|
Restricted Stock Units |
(5) |
(5) |
Common Stock |
3134 |
(6) |
D |
|
Restricted Stock Units |
(7) |
(7) |
Common Stock |
3859 |
(6) |
D |
|
Restricted Stock Units |
(8) |
(8) |
Common Stock |
4427 |
(6) |
D |
|
Explanation of
Responses: |
(1) |
25% of the 70,000 shares
originally subject to the stock option vested and became
exercisable on July 16, 2019, and the remaining shares vest and
become exercisable in 36 equal monthly installments
thereafter. |
(2) |
25% of the shares subject to
the Stock Option vested and became exercisable on April 29, 2020,
and the remaining shares vest and become exercisable in 36 equal
monthly installments thereafter. |
(3) |
25% of the shares subject to
the Stock Option vested and became exercisable on January 6, 2021,
and the remaining shares vest and become exercisable in 36 equal
monthly installments thereafter. |
(4) |
25% of the shares subject to
the Stock Option vest and become exercisable on February 23, 2022,
and the remaining shares vest and become exercisable in 36 equal
monthly installments thereafter. |
(5) |
50% of the shares subject to
the restricted stock units vest on each of April 29, 2022 and April
29, 2023. |
(6) |
Each restricted stock unit
represents a contingent right to receive one share of the Issuer's
common stock. |
(7) |
One-third of the shares
subject to the restricted stock units vest on each of January 6,
2022, January 6, 2023 and January 6, 2024. |
(8) |
The restricted stock units
vest in four equal annual installments beginning February 23,
2022. |
Reporting
Owners
|
Reporting Owner Name / Address |
Relationships
|
Director |
10% Owner |
Officer |
Other |
Teehan Brendan
C/O ACADIA PHARMACEUTICALS INC.
12830 EL CAMINO REAL, SUITE 400
SAN DIEGO, CA 92130 |
|
|
EVP, COO, Head of Commercial |
|
Signatures
|
/s/ Austin D. Kim,
Attorney-in-Fact |
|
11/5/2021 |
**Signature of Reporting
Person |
Date |
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From Apr 2022 to May 2022
Acadia Pharmaceuticals (NASDAQ:ACAD)
Historical Stock Chart
From May 2021 to May 2022